Hala Zreiqat | |
---|---|
Personal details | |
Born | Jordan |
Nationality | Jordanian Australian |
Occupation | Biomechanical engineer |
Hala Zreiqat is a biomechanical engineer whose research focuses on the development of novel engineered synthetic materials and 3D printed platforms for regenerative medicine. She is a Payne-Scott Professor in the Department of Biomechanical Engineering at the University of Sydney.
Zreiqat was born in Jordan. However, she grew up in the West Bank, before returning to Jordan to study biology at the University of Jordan in Amman. She received a scholarship for her studies attached to a commission in the Jordanian Armed Forces. After graduation she worked at the King Hussein Medical Centre, where she was officially a First lieutenant. [1] [2]
In 1991, Zreiqat moved to Australia to study a PhD in Medical Sciences at the University of New South Wales. [2]
From 2010 to 2012, she was President of the Australian and New Zealand Orthopaedic Research Society, the first woman to be the Society's president. [3] [4]
In 2016/17, Zreiqat undertook a Radcliffe Fellowship at Harvard University, the first person from NSW to do so. The focus of her fellowship was to develop educational and industry research collaborations between Australia and the United States in her research area of musculoskeletal disorders and biomaterials, and to gain skills in rapid research translation and commercialisation. [5]
Since 2018, she has been the Director of the Australian Research Council (ARC) Training Centre for Innovative BioEngineering. The centre aims to create technologies to improve treatments and outcomes for challenging medical conditions; develop a data capture framework for continuous improvement of technologies; and produce a skilled workforce to advance this work in the future. [6]
In 2019, she was made a Member of the Order of Australia for "... significant service to biomedical engineering, and to research councils" [7] and in 2020, she was nominated for, and awarded, a Payne-Scott Professorial Distinction from the University of Sydney, which recognises "sustained academic achievement and dedication to the University's values, and for playing an active role in developing strategic initiatives, and [...] outstanding contributions to the University community." [8]
In 2021, she was awarded a Fulbright Senior Scholarship to work at Massachusetts Institute of Technology alongside Professor Robert Langer. The focus of her scholarship was to learn about research translation and commercialisation to then apply this to the commercialisation of regenerative medicine research in Australia. [9]
Zreiqat's work focuses on creating new engineered synthetic materials and developing technologies to 3D print replacement body parts for people suffering from injury and disease, particularly in orthopaedic, dental and maxillofacial contexts. [10] [11] She holds a number of patents for her novel materials. [12]
One strand of her research has looked at creating a scaffold that will stimulate bone regrowth at sites of injury or defect. The scaffold is made of a novel ceramic containing trace elements and nanoparticles needed for bone growth. The ceramic is porous to allow blood and nutrients to infiltrate. The scaffold can be 3D printed to match the defect site and will degrade in the body as it is replaced by bone. This technology could be used to replace metal implants which have a finite lifespan, thus reducing the need for repeat surgeries and the associated time, costs and risk of complications. [13] [14]
In 2019, she was awarded the ANSTO Eureka Prize for Innovative Use of Technology for this research [15] as well as a place on the list of Australia's most Innovative Engineers (2020). [16]
Through research in collaboration with the Children's Medical Research Institute (CMRI) at Westmead, Zreiqat and her team have used 3D photolithographic printing to guide stem cells to form organised structures. Using bioengineering and cell culture techniques, the team created stem cells from blood and skin cells. They then used chemical and mechanical signals to replicate the natural developmental process to support the cells to create organised tissues. This technology has potential future implications in developing organs for transplant and treating vision loss as a result of macular degeneration. [17] [18]
Zreiqat's team has also developed a synthetic substance that could mimic or replace tendon and ligament tissue, potentially speeding up recovery from injury. In a collaboration with Columbia University and the University of Erlangen-Nuremberg, researchers have developed fibre-reinforced hydrogel scaffolds which have the same stress resistance and water volume as real tissue which should support collagen growth. [19] [20] [21]
In addition to her research work, Zreiqat has founded projects to improve access to opportunities for women and young scientists. In recognition of her contributions to regenerative medicine and orthopaedic research in NSW and commitment to improving opportunities for women around the world, Zreiqat was named the 2018 NSW Premier's Woman of the Year. [22] [23]
BIOTech Futures aims to inspire students' passion for technology and innovation. Early-career researchers and undergraduate students work with high school teachers and students to tackle biotechnology challenges. [24]
IDEAL (Inclusion Diversity Equity Action Leadership) Society, an international, intergenerational, interdisciplinary network, supported by the University of Sydney and Harvard University, which aims to "transform society so that both women and men can pursue their dreams, fulfill their potential, exercise leadership, and be respected for their achievements." [25]
Zreiqat is a board member and chair (2020-2027) of the Council for Australian-Arab Relations (CAAR), which aims to "broaden and strengthen Australian-Arab relations by advancing areas of shared political, economic, and social interest and building a greater appreciation of each other's cultures and values." [26]
Tissue engineering is a biomedical engineering discipline that uses a combination of cells, engineering, materials methods, and suitable biochemical and physicochemical factors to restore, maintain, improve, or replace different types of biological tissues. Tissue engineering often involves the use of cells placed on tissue scaffolds in the formation of new viable tissue for a medical purpose, but is not limited to applications involving cells and tissue scaffolds. While it was once categorized as a sub-field of biomaterials, having grown in scope and importance, it can be considered as a field of its own.
Jennifer A. Lewis is an American materials scientist and engineer, best known for her research on colloidal assembly of ceramics and 3D printing of functional, structural, and biological materials.
Gordana Vunjak-NovakovicFRSC is a Serbian American biomedical engineer and university professor. She is a University Professor at Columbia University, as well as the Mikati Foundation Professor of Biomedical Engineering and Medical Sciences. She also heads the laboratory for Stem Cells and Tissue Engineering at Columbia University. She is part of the faculty at the Irving Comprehensive Cancer Center and the Center for Human Development, both found at Columbia University. She is also an honorary professor at the Faculty of Technology and Metallurgy at the University of Belgrade, an honorary professor at the University of Novi Sad, and an adjunct professor at the Department of Biomedical Engineering at Tufts University.
The Network of Excellence for Functional Biomaterials (NFB) is a multidisciplinary research centre which hosts over sixty biologists, chemists, scientists, engineers and clinicians. It is based at the National University of Ireland, Galway, and is directed by Professor Abhay Pandit.
Three dimensional (3D) bioprinting is the use of 3D printing–like techniques to combine cells, growth factors, bio-inks, and biomaterials to fabricate functional structures that were traditionally used for tissue engineering applications but in recent times have seen increased interest in other applications such as biosensing, and environmental remediation. Generally, 3D bioprinting uses a layer-by-layer method to deposit materials known as bio-inks to create tissue-like structures that are later used in various medical and tissue engineering fields. 3D bioprinting covers a broad range of bioprinting techniques and biomaterials. Currently, bioprinting can be used to print tissue and organ models to help research drugs and potential treatments. Nonetheless, translation of bioprinted living cellular constructs into clinical application is met with several issues due to the complexity and cell number necessary to create functional organs. However, innovations span from bioprinting of extracellular matrix to mixing cells with hydrogels deposited layer by layer to produce the desired tissue. In addition, 3D bioprinting has begun to incorporate the printing of scaffolds which can be used to regenerate joints and ligaments. Apart from these, 3D bioprinting has recently been used in environmental remediation applications, including the fabrication of functional biofilms that host functional microorganisms that can facilitate pollutant removal.
Michelle Yvonne Simmons is an Australian quantum physicist, recognised for her foundational contributions to the field of atomic electronics.
The in vivo bioreactor is a tissue engineering paradigm that uses bioreactor methodology to grow neotissue in vivo that augments or replaces malfunctioning native tissue. Tissue engineering principles are used to construct a confined, artificial bioreactor space in vivo that hosts a tissue scaffold and key biomolecules necessary for neotissue growth. Said space often requires inoculation with pluripotent or specific stem cells to encourage initial growth, and access to a blood source. A blood source allows for recruitment of stem cells from the body alongside nutrient delivery for continual growth. This delivery of cells and nutrients to the bioreactor eventually results in the formation of a neotissue product.
Muscle tissue engineering is a subset of the general field of tissue engineering, which studies the combined use of cells and scaffolds to design therapeutic tissue implants. Within the clinical setting, muscle tissue engineering involves the culturing of cells from the patient's own body or from a donor, development of muscle tissue with or without the use of scaffolds, then the insertion of functional muscle tissue into the patient's body. Ideally, this implantation results in full regeneration of function and aesthetic within the patient's body. Outside the clinical setting, muscle tissue engineering is involved in drug screening, hybrid mechanical muscle actuators, robotic devices, and the development of engineered meat as a new food source.
Peter Philip Gray is a bioengineer who has played a key role in the development of modern industrial biotechnology in Australia. He was professor and head of biotechnology at the University of New South Wales (UNSW), Sydney, from 1988–2003, and was the inaugural director of the Australian Institute for Bioengineering and Nanotechnology (AIBN) at The University of Queensland in Brisbane, Australia from 2003–2015.
Anthony Steven Weiss is an Australian university researcher, company founder and entrepreneur. He is the leading scientist in human tropoelastin research and synthetic human elastin. He holds the McCaughey Chair in Biochemistry, heads the Charles Perkins Centre Node in Tissue Engineering and Regenerative Medicine, and is Professor of Biochemistry and Molecular Biotechnology at the University of Sydney. His discoveries are on human elastic materials that accelerate the healing and repair of arteries, skin and 3D human tissue components. He is a Fellow of the Royal Society of Chemistry. Weiss is on the editorial boards of the American Chemical Society Biomaterials Science and Engineering, Applied Materials Today (Elsevier), Biomaterials, Biomedical Materials, BioNanoScience (Springer) and Tissue Engineering. He is a biotechnology company founder, promoter of national and international technology development, and has received national and international awards, including the Order of Australia.
Treena Livingston Arinzeh is an American biomedical engineer and academic.
Nina Marie Tandon is an American biomedical engineer. She is the CEO and co-founder of EpiBone. She is an adjunct professor of Electrical Engineering at Cooper Union and is a senior fellow at the Lab for Stem Cells and Tissue Engineering at Columbia. She was a 2011 TED Fellow and a 2012 senior TED Fellow.
Antonios Georgios Mikos is a Greek-American biomedical engineer who is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He specialises in biomaterials, drug delivery, and tissue engineering.
Susan Margaret Pond is an Australian scientist and technologist, active in business and academia, and recognised for her contributions to medicine, biotechnology, renewable energy and sustainability. She is the current president of the Royal Society of New South Wales.
Erin Baker Lavik is an American bioengineer serving as the deputy director and chief technology officer of the National Cancer Institute's Division of Cancer Prevention (DCP) since 2023. She was previously a professor of chemical, biochemical, and environmental engineering at the University of Maryland, Baltimore County. Lavik develops polymers and nanoparticles that can protect the nervous system. She is a fellow of the American Institute for Medical and Biological Engineering.
Prof. Vicki Chen is an Australian engineer, a former Executive Dean for the Faculty of Engineering, Architecture and Information Technology at the University of Queensland, and current Provost and Senior Vice-President of the University of Technology Sydney.[10] In 2020 she was elected as the Fellow of Australian Academy of Technology and Engineering.
Susmita Bose is an Indian-American scientist and engineer, best known for her research on biomaterials, 3D printing or additive manufacturing of bone implants and natural medicine. She is the Herman and Brita Lindholm Endowed Chair Professor in the School of Mechanical and Materials Engineering at Washington State University.
Jennifer L. West is an American bioengineer. She is the current Dean of Engineering and Applied Science at the University of Virginia. She was the Fitzpatrick University Professor of Biomedical Engineering at Duke University from 2012-2021. In 2000, West cofounded Nanospectra Biosciences in Houston to develop a cancer therapy based on gold nanoparticles that destroy tumor cells and has been listed by MIT Technology Review as one of the 100 most innovative young scientists and engineers world wide.
Tatiana Segura is an American biomedical engineer who is a professor at Duke University. Her research considers biomedical engineering solutions to promote cell growth. She was elected Fellow of the American Institute for Medical and Biological Engineering in 2017 and awarded the Acta Biomaterialia Silver Medal in 2021.
Therese Flapper is an Australian environmental engineer, and was elected to be a fellow of the Australian Academy of Technological Sciences and Engineering, in 2023. She has worked with infrastructure including water, roads, waste, energy and buildings, and was past president of Engineers Australia, Canberra, and the local Landcare group.
{{cite web}}
: Missing or empty |title=
(help){{cite web}}
: External link in |title=
(help)